Industrial Crystallizers Market to Reach USD 5.87 Billion by 2032 with a CAGR of 4.67%, Driven by Demand for High-Purity Materials and Wastewater Treatment Innovations
Industrial Crystallizers Market is experiencing significant growth driven by the increasing need for high-purity substances in the chemical, pharmaceutical, and food industries. As industrial processes become more complex, crystallization technologies are essential for efficient separation and purification.
Austin, May 27, 2025 (GLOBE NEWSWIRE) -- The Industrial Crystallizers Market Size was valued at USD 3.91 billion in 2023 and is expected to reach USD 5.87 billion by 2032, growing at a CAGR of 4.67% over the forecast period from 2024 to 2032.Download PDF Sample of Industrial Crystallizers Market @ https://www.snsinsider.com/sample-request/6592
The industrial crystallizers market is growing due to the need for high-purity substances, especially in the pharmaceuticals and chemicals industries. The rising use of crystallization technologies in the treatment of wastewater and the food industry also drives up market demand. Forced circulation systems and continuous processes are notable advancements in crystallizer design and are finding their way into mass production owing to their improved efficiency, scalability, higher yield quality consistency, as well as secondary treatment mechanisms, which are driving growth in the key regions across the globe.
U.S. Industrial Crystallizers Market to Reach USD 1.07 Billion by 2032 with 6.15% CAGR
The U.S. Industrial Crystallizers Market reached USD 0.63 billion in 2023 and is expected to reach USD 1.07 billion by 2032, advancing at a CAGR of 6.15% from 2024 to 2032. The U.S. market for industrial crystallizers is a key driver of global growth, spurred by innovation in chemical production, pharmaceuticals, and wastewater treatment.
Key Players:
Tsukishima Kikai – (OS Crystallizer, Vacuum Cooling Crystallizer)
Fives Group – (Evaporative Crystallizer, Solios Forced Circulation Crystallizer)
Condorchem Envitech – (ENVIDEST MVR FC Crystallizer, Vacuum Crystallization Plant)
Vobis LLC – (Pilot Plant Crystallizer, Continuous Crystallizer System)
Anssen Metallurgy Group Co., Ltd. – (Vacuum Salt Crystallizer, Evaporation & Crystallization System)
Boardman LLC – (Forced Circulation Crystallizer, Industrial Heat Exchanger Crystallizer)
Chemin Enviro Systems Pvt. Ltd. – (Forced Circulation Crystallizer, Agitated Thin Film Dryer-Crystallizer Combo)
DCI, Inc. – (Batch Crystallizer Tank, Jacketed Stainless Steel Crystallizer)
Ebner GmbH & Co. KG – (Vacuum Crystallizer, Controlled Cooling Crystallizer)
Ekato Holding GmbH – (EKATO ISOPAS Crystallizer, EKATO UNIMIX Processing Crystallizer)
Excel Engineering – (MS ZLD Crystallizer, Multiple Effect Evaporator with Crystallizer)
GEA Group – (GEA MSE Crystallizer, VARICHEMA Batch Crystallizer)
Katsuragi Industry Co., Ltd. – (Stainless Steel Crystallizer Tank, Continuous Crystallizing Unit)
KEP Engineering Services Pvt. Ltd. – (Forced Circulation Crystallizer, Agitated Crystallizer)
Moretto S.p.A. – (XD 800 X Dryer-Crystallizer, DEGA Thermal Crystallizer)
Motan Colortronic Ltd. – (LUXOR CA S Crystallizer, METRO G Crystallizing Loader)
Paul Mueller Company – (Skid-Mounted Crystallizer System, Sanitary Batch Crystallizer)
Vattenfall AB – (Electric Boiler for District Heating, Power-to-Heat Industrial Boiler System)
Industrial Crystallizers Market Report Scope:
Report Attributes
Details
Market Size in 2023
USD 3.91 Billion
Market Size by 2032
USD 5.87 Billion
CAGR
CAGR of 4.67% From 2024 to 2032
Base Year
2023
Forecast Period
2024-2032
Historical Data
2020-2022
Report Scope & Coverage
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments
• By Type – (DTB Crystallizers, Forced Circulation Crystallizers, Fluidized Bed Crystallizers, Others)• By Process – (Continuous, Batch)• By End-Use Industry – (Pharmaceutical, Agrochemical, Metal & Mineral, Food & Beverage, Chemical, Wastewater Treatment, Others)
Key Drivers
• Rising Adoption of Crystallization in Wastewater Treatment Drives the Industrial Crystallizers Market Growth.
If You Need Any Customization on Industrial Crystallizers Market Report, Inquire Now @ https://www.snsinsider.com/enquiry/6592
Key Segments Driving Growth in the Industrial Crystallizers Market: Insights by Type, Process, and End-Use Industry
By Type: In terms of type, the Forced Circulation Crystallizers segment led the industrial crystallizers market with a 41.29% revenue share in 2023. The domination of this segment is due to the high processing efficiency of a large volume and corrosive solution. Its forced circulation design provides an efficient means of heat removal, resulting in reproducible crystallization behavior during extreme operational conditions. Such characteristics make them especially appropriate for the chemical and pharmaceutical, and food processing industries, where it is necessary to work with aggressive solvents and in high-throughput operations.
By Process: The Continuous segment led the industrial crystallizers market in 2023 with a revenue share of 60.58%. This process ensures high efficiency in mass production and constant quality of product, leading to this leadership. Chemicals, fertilizers, and other high-demand sectors, where production must be uninterrupted and in large quantities for cost-effectiveness, highly value the continuous crystallization process. It enables a constant flow of operation, where the downtime is statistically negligible and output is maximized. With more industries emphasizing efficiency and scale, continuous crystallizers will keep their title as the equipment of choice for applications that demand a steady supply of quality crystallized end-products.
By End-Use Industry: In 2023, the Chemical industry accounted for the highest revenue share in the market for industrial crystallizers, given its requirement for large-scale separation and purification operations. As a result, the industry has a high demand for industrial-scale separation and purification processes where crystallization is a pivotal process technology. Examples, including chemicals, pharmaceuticals, and specialty materials, often require specific purity levels that can only be achieved through precise crystallization. Industrial crystallizers are essential to the chemical sector due to their capability to rapidly isolate elements from lithified mixtures and maintain product quality reliability.
Asia Pacific Dominates Industrial Crystallizers Market, North America Poised for Rapid Growth
In 2023, the Asia Pacific region held the highest revenue share of 39.68% in the industrial crystallizers market, which was mainly supported by the high growth of major industries like chemicals, pharmaceuticals, and wastewater treatment, particularly in China, India, and Southeast Asia. The use of industrial crystallizers for separation & purification in these end-use industries will drive the market demand. The growing manufacturing and production sector in these countries has resulted in increased investment in infrastructure and technology, which is further driving the demand for effective crystallization. Thus, Expansion of the industrial base in the area contributes towards the growth of the market as industries require advanced technologies to streamline the process and meet regulatory standards.
North America is expected to witness the highest compound annual growth rate (CAGR) of 6.23% in the industrial crystallizers market during the forecast period. This growth is mainly attributed to the modified environmental guidelines that encourage industries to organize efficient wastewater treatment systems. More stringent regulations are driving the need for advanced technologies in industrial crystallizers to comply with those regulations. Moreover, demand for crystallizers is accelerating due to the robust growth of the region's pharmaceutical sector. These systems are increasingly being adopted in the pharmaceutical sector, where precise crystallization processes are necessary for drug production.
Recent Development
In October 2024: Fives participated in Glasstec 2024, where it highlighted its decarbonized glass manufacturing solutions. The company demonstrated its electric melting technologies, hybrid systems, and oxy-fuel combustion solutions, all designed to reduce CO₂ emissions and improve energy efficiency in glass production.
In May 2024: Moretto took part in Plastpol 2024, showcasing its latest innovations focused on energy efficiency, advanced technology, customization, and sustainability. The company presented its DGM Gravix series, renowned for its precision in dosing, and the DPK 8, which is engineered for micro-dosing applications in plastic processing.Buy Full Research Report on Industrial Crystallizers Market 2024-2032 @ https://www.snsinsider.com/checkout/6592
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Industrial Crystallizers Market Segmentation, By Process
8. Industrial Crystallizers Market Segmentation, By End-Use Industry
9. Industrial Crystallizers Market Segmentation, By Type
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practice
13. Conclusion
Read Our Trending Reports:
North America Led Industrial Air Filtration Market in 2023 with 44% Revenue Share Driven by Air Quality Awareness and Regulations
North America Dominated Industrial Pumps Market with Over 43% Share in 2023 Driven by Chemical and Oil Industries
Industrial Robotics Market in Europe Set for Significant Growth Driven by Collaborative Robots Enhancing Industrial Automation
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
37 minutes ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
an hour ago
- Yahoo
PingPong Expands Leading B2B Cross-Border Payments Platform Into Malaysia, Further Unlocking Southeast Asia For Enterprise Clients
PingPong has been granted a Money Services Business Licence Class B from Malaysia's central bank, Bank Negara Malaysia, unlocking a USD $445 billion economy for enterprises, financial institutions, and SaaS companies expanding into and out of Malaysia. This follows PingPong's recent expansion into Indonesia and existing presence in Vietnam, Thailand, Singapore, and the Philippines, further expanding PingPong's comprehensive portfolio of over 60 global licences. KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ -- PingPong, the world-leading provider of cross-border embedded payment solutions for enterprises, is pleased to announce that it has been granted a Money Services Business Licence from Malaysia's central bank, Bank Negara Malaysia. This latest licence further enhances PingPong's extensive portfolio of over 60 global licences, unlocking even more cross-border opportunities for enterprises on PingPong's platform. Malaysia offers significant growth opportunities for enterprises looking to scale in Southeast Asia. Its GDP is expected to reach $445 billion USD by the end of 2025 and grow by 33% by 2030, reaching $600 billion USD. International trade is a significant part of Malaysia's wealth, valued at 132% of GDP in 2023. Financial services and fintech companies are thriving across Southeast Asia, with Malaysia emerging as a key player. The country ranks third in the region in terms of the number of fintech companies it has, and it is poised for significant growth. Malaysia's fintech sector is projected to double, from $54 billion USD in 2025 to $111 billion USD by 2030, reflecting a robust compound annual growth rate (CAGR) of 16%. Its strategic location, high digital adoption rate, and robust financial sector have made it one of the key growing countries in Southeast Asia. Jianqin Shu, Partner and APAC General Manager at PingPong, said, "As one of the most strategically positioned and rapidly growing economies in Southeast Asia, Malaysia presents an incredible opportunity for enterprises scaling their global operations. Securing a Money Services Business licence positions PingPong at the heart of this growth, empowering us to support Malaysia's expanding fintech and financial services ecosystem, meeting the rising demand for efficient, compliant cross-border payment solutions. This milestone enables us to extend our global reach further and provide enterprises with end-to-end, one-stop payment services." This approval from Bank Negara Malaysia further adds to PingPong's significant portfolio of over 60 global licences across the United States, EU, UK, Hong Kong, mainland China, Canada, Australia, Japan, Singapore, Indonesia and other countries and regions worldwide. About us PingPong was founded in New York in 2015, with the goal of solving the immense challenge of scaling enterprise businesses globally. Fast forward to today, and PingPong has become one of the world's leading global cross-border payments platforms, processing more than $250 billion USD. Our API-first cross-border payments platform integrates with enterprises to send, manage, and receive money faster on a global scale. PingPong currently has 37 offices in 15 countries and 1,500 employees. Our international presence helps businesses solve complex payment needs in every major economy across all time zones. Logo - Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Electric Motors Market Share Expected to Grow $206.4 Billion by 2029
Delray Beach, FL, June 01, 2025 (GLOBE NEWSWIRE) -- The global Electric Motors Market share is expected to grow from USD 152.2 billion in 2024 to USD 206.4 billion by 2029, at a CAGR of 6.3% during forecast period. Electric motors market is driven mainly by Increasing demand for HVAC systems among residential, commercial, and industrial end-users, growing demand for electric motors in manufacturing industries, and rising demand for energy-efficient motors. The electric motor market has bloomed forth globally. All these sectors inherit demanding environments for solving problems and improving reliability. From electric vehicles to industrial machinery, consumer electronics to wind turbines, electric motors find applications in many areas. They not only ensure low energy consumption but also increase efficiency and reduce operating costs. As the world population grows and economies expand, the demand for energy, particularly oil and gas, continues to rise. Increasing demand for HVAC (Heating, Ventilation, and Air Conditioning) systems among residential, commercial, and industrial end-users, industries shift towards energy-efficient electric motors due to lowered energy utilization and operational costs in manufacturing industries are some of the major driving factors for the electric motors market. Download PDF Brochure: List of Key Players in Electric Motors Market: ABB (Switzerland) Siemens (Germany) WEG (Brazil) Wolong Electric (China) NIDEC CORPORATION (Japan) Drivers, Opportunities and Challenges in Electric Motors Market: Driver: Increasing demand for HVAC systems in residential, commercial, and industrial sectors Restraint: Fluctuating prices of raw materials Opportunity: Transition in the global automotive industry toward electric vehicles Challenge: Shortage of components and supply chain issues Electric mobility is making a huge transition in the global automobile industry. The proactive efforts for the decarbonization of society in Europe are driven by the ever-increasing share of electric motors in the market. Advancements in battery technologies have reduced costs of batteries and improved the charging speed of the batteries. The increase in government support by providing redemptions on tax and incentives for promoting eco-friendly electric vehicles through electric motors are also acts of opportunities for the growth of the electric motors market. As per the IEA, it is revealed that 50% of global passenger electric vehicles should come from China in the year 2025. Many governments worldwide are implementing policies and incentives to promote the adoption of electric vehicles as part of efforts to reduce greenhouse gas emissions and combat climate change. These policies include subsidies for EV purchases, tax incentives, and stricter emissions regulations, all of which are accelerating the transition to electric mobility and, consequently, increasing demand for electric vehicle motor market. The rapid growth of the EV market has led to the construction of new manufacturing facilities dedicated to producing electric vehicles and their components, including electric motors. Major automakers and new EV startups are investing heavily in scaling up production, which includes securing a reliable supply of electric motors. the growing demand for electric vehicles is a major driver of demand for electric motors. The transition to electric mobility, driven by technological advancements, government policies, and consumer preferences, is creating a significant and expanding market for electric motors across a wide range of vehicle types and applications. As the EV market continues to grow, the demand for efficient, powerful, and innovative electric motors will remain strong.. Request Sample Pages: Asia Pacific region to be the largest electric motors market Asia Pacific is expected to dominate the global electric motor market size between 2024–2029, followed by Europe and North America. The urban population growth drives demand for infrastructure, including commercial buildings, residential complexes, and public utilities, all of which rely heavily on electric motors for HVAC systems, elevators, water treatment, etc are the reasons for the region's significant market size. Countries such as China and India are driving demand, supported by government initiatives promoting industrial automation and renewable energy adoption. The region's large water treatment plants and increasing electric vehicle manufacturing add to the demand for high-power motors. Moreover, improving motor efficiency and compact high-density designs also increase the market further. This is driving the electric motor market size in the Asia Pacific region. Related Reports: Brushless DC Motor Market - Global Forecast to 2028 Energy Efficient Motor Market - Global Forecast to 2028 CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@ Visit Our Website:
